India Pharma Outlook Team | Tuesday, 06 January 2026
Jaguar Health today announced it has secured a $240,000 FDA grant to advance research on a treatment for chemotherapy-induced diarrhea in dogs, a serious and often dangerous side effect of cancer care.
The company said it received notice on January 1 from the US Food and Drug Administration’s Center for Veterinary Medicine. The funding will support an ongoing effectiveness study of Canalevia-CA1, which is currently conditionally approved for chemotherapy-induced diarrhea in dogs.
“As announced on December 10, 2025, the FDA granted renewal of the conditional approval for Canalevia-CA1 for a fifth and final year…Jaguar must complete and file a successful effectiveness study,” said Michael Guy, Jaguar’s Vice President of Preclinical and Nonclinical Studies.
Also Read: India's Innovative Therapies Set Global Standard at Low Cost
Dogs undergoing chemotherapy are adopted as a good experience of learning how cancerous drugs can cause diarrhea in humans. Most drugs used to treat dogs are identical to or similar to drugs used to treat humans, and therefore, can produce the same side effects.
The problem is big. The American Veterinary Medical Foundation estimates the number of dogs in the US to be approximately 90 million in 2024. According to Jaguar Health over 11 million dogs contract general diarrhea annually. By industry figures, 104 million dogs existed in Europe in 2022.
Another concern which was raised by Jaguar is that Canalevia is not an antibiotic, because antibiotic resistance is a rising concern among both animals and humans.
One of the primary causes of dogs visiting the vet and the second cause of emergency visit to the vet is diarrhea. Although it has its risks, a non-infectious, general diarrhea treatment in dogs has not been approved by the FDA. Canalevia-CA1 is also attempting to close that gap in an effort to be completely approved.
.jpg)
.jpg)
